From one Dragon to another as SpaceX Crew-10 prepares to return to Earth
McClain, fellow NASA astronaut Nichole Ayers, Japanese astronaut Takuya Onishi of JAXA, and Russian cosmonaut Kirill Peskov of Roscosmos, are part of SpaceX's Crew-10 and are set to return to Earth inside Crew Dragon Endurance shortly after midday on Thursday — assuming the weather conditions are suitable at the splashdown site off the coast of Florida.
Recommended Videos
McClain and her Crew-10 colleagues have spent the last week showing the ropes to Crew-11, who arrived aboard another Crew Dragon spacecraft.
The American astronaut posted a striking image on X on Wednesday, taken from one of the Dragon spacecrafts and showing the other one, with Earth directly below and an aurora in the far distance.
'Dragon Endurance and Crew-10 are settled in for our last night aboard the Space Station,' McClain wrote in her post. 'When there are two crews aboard during handover, we get this unique view from the zenith-docked Dragon looking down at the forward-docked Dragon. Tomorrow, Crew-10 will strap ourselves into this Dragon and head home. But tonight, one more breathtaking view.'
Dragon Endurance and Crew-10 are settled in for our last night aboard @Space_Station. When there are two crews aboard during handover, we get this unique view from the zenith-docked Dragon looking down at the forward-docked Dragon. Tomorrow, Crew-10 will strap ourselves into this… pic.twitter.com/ZiYlLlsS1H — COL Anne McClain (@AstroAnnimal) August 6, 2025
In another post on X, McClain said she found it hard to believe that her time in orbit was 'coming to a close already,' adding, 'What a great trip this has been.'
In their five months aboard the ISS, Crew-10 spent much of their time conducting science research in microgravity.
The work included an investigation into how radiation and gravity environments at different orbital altitudes affect plant growth — important for future long-duration crewed missions to deep space — and a look at how cells sense gravity, with the findings possibly leading to therapies for treating muscle and bone conditions.
They also captured images of simultaneous lightning events at the top of two thunderstorms, with scientists using such data to study various weather conditions in Earth's upper atmosphere. The research can help to better protect communication systems and aircraft while improving atmospheric models and weather forecasts.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
17 minutes ago
- Yahoo
Tempus AI Raises Outlook, CEO Cites Faster-Than-Expected Growth And Improved Margins
Tempus AI Inc. (NASDAQ:TEM) reported second-quarter financial results Friday. The AI-focused precision medicine and patient care company reported a second-quarter adjusted loss of 22 cents per share, beating analyst estimates for a loss of 24 cents per share. Tempus AI reported quarterly revenue of $314.64 million, beating the consensus estimates of $296.85 million. Revenue increased 89.6% year-over-year. Genomics contributed $241.8 million in revenue in the quarter, growing 115.3% year over testing (Tempus genomics) delivered $133.2 million of revenue, up 32.9%, with approximately 26% volume growth versus 20% last quarter. Hereditary testing sales (Ambry genetics) reached $97.3 million, up 33.6% year-over-year on a pro forma basis with approximately 32% volume growth. Revenue from Data and services totaled $72.8 million, delivering 35.7% growth versus the second quarter of 2024, led by Insights (data licensing), which grew 40.7% year-over-year. Adjusted EBITDA of ($5.6 million) in the second quarter of 2025 compared to ($31.2 million) in the second quarter of 2024, an improvement of $25.6 million year-over-year. View more earnings on TEM 'The business is performing well with revenues and margins growing faster than expected, contributing to our continued improvement in adjusted EBITDA on a year-over-year basis,' said Eric Lefkofsky, Founder and CEO of Tempus. 'We saw significant re-acceleration of our clinical volumes, which grew 30% in the quarter, as we delivered more than 212,000 NGS tests,' Lefkofsky said in a statement on Friday. Database Update Through more than 4,500 integrations, Tempus said it connected to more than 40 million clinical patient records, with around 9 million de-identified and ingested, spanning approximately 1.1 billion healthcare documents, a significant percentage of which are connected to the around 4 million samples the company has sequenced. As a result, the company's database stands at over 350 petabytes of connected clinical and molecular data. Tempus AI ended the quarter with $293.0 million in cash and marketable securities, an improvement of around $70 million over last quarter. Outlook Tempus AI increased its guidance and expects a full year of 2025 revenue of approximately $1.26 billion for the consolidated business, representing approximately 82% annual growth, compared to the consensus of $1.25 billion. Earlier, the company expected revenue between $1.24 billion and $1.25 billion for its consolidated Tempus and Ambry Genetics business. The company reaffirms full-year 2025 adjusted EBITDA of $5 million, an improvement of approximately $110 million over 2024. Tempus AI received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its ejection fraction software in July. Tempus said the FDA granted it 510(k) clearance for its Tempus ECG-Low EF software, which uses AI to identify patients with a potential left ventricular ejection fraction. Price Action: Tempus AI shares were up 5.79% after hours, trading at $55.21 at the time of publication on Tuesday. Read Next:Photo by Piotr Swat via Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? This article Tempus AI Raises Outlook, CEO Cites Faster-Than-Expected Growth And Improved Margins originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved.
Yahoo
17 minutes ago
- Yahoo
BrainStorm to Announce Second Quarter Financial Results and Provide a Corporate Update
Call Scheduled for August 14, 2025, at 8:30 AM Eastern Time NEW YORK, Aug. 8, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that it will hold a conference call and webcast to update shareholders on financial results for the second quarter of 2025, at 8.30 a.m. Eastern Time on August 14, 2025. BrainStorm's President and Chief Executive Officer, Chaim Lebovits, will provide the update. Hartoun Hartounian, PhD, Chief Operating Officer, Bob Dagher, MD, Chief Medical Officer, and Alla Patlis, Interim Chief Financial Officer, will also participate in the call. Following the prepared remarks, there will be a Q&A session with the investment community. Participants are encouraged to submit their questions in advance of the call by sending them to: q@ Questions should be submitted by 10:00 a.m. Eastern Time on August 12, 2025. The investment community may participate in the conference call by dialing the following numbers: Investor dial in:U.S. Toll Free: 877-545-0320 International: 973-528-0002 Participant Access Code: 601260 Webcast URL: Those that wish to listen to the replay of the conference call can do so by dialing the numbers below. The replay will be available until August 28, 2026. Teleconference Replay Number: Toll Free: 877-481-4010 International: 919-882-2331 Replay Passcode: 52831 About BrainStorm Cell Therapeutics Inc. BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI) is a leading developer of autologous adult stem cell therapies for debilitating neurodegenerative diseases. The company's proprietary NurOwn® platform uses autologous mesenchymal stem cells (MSCs) to produce neurotrophic factor-secreting cells (MSC-NTF cells), designed to deliver targeted biological signals that modulate neuroinflammation and promote neuroprotection. NurOwn® is BrainStorm's lead investigational therapy for amyotrophic lateral sclerosis (ALS) and has received Orphan Drug designation from both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). A Phase 3 trial in ALS (NCT03280056) has been completed, and a second Phase 3b trial is set to launch under a Special Protocol Assessment (SPA) agreement with the FDA. The NurOwn clinical program has generated valuable insights into ALS disease biology, including pharmacogenomic response associated with the UNC13A genotype, biomarker data collected at seven longitudinal time points, and a comprehensive analysis of the "Floor Effect" - a critical challenge in measuring clinical outcomes in advanced ALS. BrainStorm has published its findings in multiple peer-reviewed journals. In addition to ALS, BrainStorm has completed a Phase 2 open-label multicenter trial (NCT03799718) of MSC-NTF cells in progressive multiple sclerosis (MS), supported by a grant from the National MS Society. BrainStorm is also advancing a proprietary, allogeneic exosome-based platform designed to deliver therapeutic proteins and nucleic acids. The company recently received a Notice of Allowance from the U.S. Patent and Trademark Office for a foundational patent covering its exosome technology, further strengthening BrainStorm's growing IP portfolio in this emerging area of regenerative medicine. To learn more, visit Notice Regarding Forward-Looking Statements This press release contains "forward-looking statements" that are subject to substantial risks and uncertainties, including statements regarding meetings with the U.S. Food and Drug Administration (FDA), Special Protocol Assessment (SPA), the clinical development of NurOwn as a therapy for the treatment of ALS, the future availability of NurOwn to patients, and the future success of BrainStorm. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will" "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on BrainStorm's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. These potential risks and uncertainties include, without limitation, management's ability to successfully achieve its goals, BrainStorm's ability to raise additional capital, BrainStorm's ability to continue as a going concern, prospects for future regulatory approval of NurOwn, whether BrainStorm's future interactions with the FDA will have productive outcomes, and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations, and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements. CONTACTS Investors:Michael Wood Phone: +1 646-597-6983 mwood@ Media:Uri Yablonka, Chief Business Officer Phone: +1 917-284-2911 uri@ Logo - View original content: SOURCE BrainStorm Cell Therapeutics Inc.
Yahoo
17 minutes ago
- Yahoo
RBL LLC secures investment from Modi Ventures
- Strategic investment to support RBL's mission to launch and scale breakthrough startups - Founder and general partner of Modi Ventures, Sahir Ali, to join RBL board of directors - Modi Ventures' Ali, RBL managing partner Wotton to speak on venture creation at Canaccord Genuity Growth Conference Aug. 12 HOUSTON, Aug. 8, 2025 /PRNewswire/ -- RBL LLC, a pioneering biotech venture creation studio dedicated to rapidly building companies based on breakthrough medical technologies, announced that it has secured an investment from Modi Ventures to support its mission to launch and scale breakthrough startups into clinical-stage companies. In addition, RBL has announced the appointment of Sahir Ali to its board of directors. Ali is the founder and current general partner of Modi Ventures, a leading venture capital firm investing in biology and technology based in Houston. Ali's experience as an accomplished technology and health care leader, investor and adviser will be instrumental in bridging the gap between academic biotech discoveries and the clinical care market. "This investment by Modi Ventures will be instrumental to RBL's growth as it reinforces confidence in our venture creation model and accelerates our ability to develop successful biotech startups," said Paul Wotton, RBL's managing partner. "Sahir's addition to the board will also amplify this collaboration with Modi. His strategic counsel and deep understanding of field-defining technologies will be invaluable as we continue to grow and deliver on our mission." "The bold thinking and entrepreneurial initiatives coming out of RBL represent an important cornerstone of the rapidly evolving Houston life sciences scene, and I am honored to contribute to this growth by joining this exceptional board," Ali said. "Partnering my new role at RBL with the investment made by Modi can truly help not only build companies but also shape the future of patient care in a collaborative and more efficient way." "Modi Ventures' investment is a strong signal of market validation for the acceleration model we've built into RBL," said Paul Cherukuri, board member of RBL and chief innovation officer of Rice University. "It reflects growing investor confidence in RBL's ability to turn breakthrough science into real-world therapies and in Houston's rise as a global force in biotech innovation." Modi Ventures employs a proprietary financial engineering framework grounded in modern portfolio theory and efficient frontier principles. With $134 million under management, Modi Ventures backs category-defining companies advancing artificial intelligence (AI)-driven drug discovery, diagnostics and engineered therapeutics. The firm also invests in leading funds across the biotech and technology spectrum. A parallel entrepreneur, scientist and innovator, Sahir has led transformative work and built companies across AI, cloud computing and precision medicine. Sahir serves on the board of directors of the Drug Information Association, a leading global life science membership association driving collaboration in drug, device and diagnostics development in pursuit of a healthier world. Sahir will join existing board members Wotton, Cherukuri, Omid Veiseh, Rima Chakrabarti, John Jaggers, Devyn Smith and James Watson, an accomplished group of leaders with deep expertise in biotech innovation, clinical translation and venture building who together provide strategic guidance to help drive RBL's continued growth and success. Wotton and Ali will participate in a panel discussion at the Canaccord Genuity 45th annual Growth Conference Aug. 12 to discuss the future of biotech venture creation and the evolving role of academic innovation in company formation. About RBL LLC: RBL LLC is a pioneering biotech venture creation studio based in Houston that is dedicated to accelerating the development of breakthrough medical technologies and therapies through company formation. RBL provides entrepreneurs, researchers and innovators with infrastructure, financial support and strategic guidance as well as access to laboratory space and shared resources in the Texas Medical Center Helix Park. For more information, please visit Media Contact: Russo PartnersDavid Schull or Liz Phillips(347) View original content: SOURCE RBL LLC
